Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

NCT04707469 on ClinicalTrials.gov · last registry update 2025-12-09

An unusually large phase 3: 1,606 participants, more than double the 424 typical for the stage. The sponsor logged completion for 7 March 2023. Primary outcome, as filed: Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 1,606
Started: 2021-01-15
Primary completion: 2023-03-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.